Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer

Cancer statistics, 2009

Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709 · see citing works

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · see citing works

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · see citing works

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848 · see citing works

Multiple Ras-dependent phosphorylation pathways regulate Myc protein stabilityPreprint

Sears, R. C., Nuckolls, F., Haura, E. B., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,379 · see citing works

A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells

Yeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791 · see citing works

CIP2A inhibits PP2A in human malignancies

Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · see citing works

Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation

Chen, J., Martin, B. L., & Brautigan, D. L. (1992) · Science · doi:10.1126/science.1325671 · Cited by 601 · see citing works

Tumor Suppressor NM23-H1 Is a Granzyme A-Activated DNase during CTL-Mediated Apoptosis, and the Nucleosome Assembly Protein SET Is Its Inhibitor

Fan, Z., Beresford, P. J., Oh, D. Y., Zhang, D., & Lieberman, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00150-8 · Cited by 541 · see citing works

Protein phosphatase 2A regulatory subunits and cancer

Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513 · see citing works

The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A

Li, M., Makkinje, A., & Damuni, Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11059 · Cited by 479 · see citing works

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu, S., Mao, H. C., Chang, J. S., Galietta, A., Uttam, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.015 · Cited by 477 · see citing works

Annual Report to the Nation on the status of cancer, 1975‐2008, featuring cancers associated with excess weight and lack of sufficient physical activity

Eheman, C. R., Henley, S. J., Ballard-Barbash, R. R., Jacobs, E. J., Schymura, M. J., Noone, A., Pan, L., Anderson, R. N., Fulton, J. E., Kohler, B., et al. (2012) · Cancer · doi:10.1002/cncr.27514 · Cited by 455 · see citing works

The Life Cycle of C-Myc: From Synthesis to Degradation

Sears, R. C. (2004) · Cell Cycle · doi:10.4161/cc.3.9.1145 · Cited by 406 · see citing works

Regulation of Phosphorylation of Thr-308 of Akt, Cell Proliferation, and Survival by the B55α Regulatory Subunit Targeting of the Protein Phosphatase 2A Holoenzyme to Akt

Kuo, Y.-C., Huang, K.-Y., Yang, C.-H., Yang, Y.-S., Lee, W.-Y., & Chiang, C.-W. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709585200 · Cited by 367 · see citing works

Multiple pathways regulated by the tumor suppressor PP2A in transformation

Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344 · see citing works

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia

Neviani, P., Santhanam, R., Oaks, J. J., Eiring, A. M., Notari, M., Blaser, B. W., Liu, S., Trotta, R., Muthusamy, N., Gambacorti-Passerini, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31095 · Cited by 337 · see citing works

A Nucleolar Isoform of the Fbw7 Ubiquitin Ligase Regulates c-Myc and Cell Size

Welcker, M., Orian, A., Grim, J. A., Eisenman, R. N., & Clurman, B. E. (2004) · Current Biology · doi:10.1016/j.cub.2004.09.083 · Cited by 311 · see citing works

First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients

Budde, K., Schmouder, R., Brunkhorst, R. R., Nashan, B., Diaeresiscker, P. W. L., Mayer, T., Choudhury, S., Skerjanec, A., Kraus, G., & Neumayer, H. H. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1341073 · Cited by 270 · see citing works

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A‐RIPK1‐dependent necroptosis

Saddoughi, S. A., Gencer, S., Peterson, Y. K., Ward, K. E., Mukhopadhyay, A., Oaks, J. J., Bielawski, J., Szulc, Z. M., Thomas, R. J., Selvam, S. P., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201283 · Cited by 265 · see citing works

Protein phosphatase 2A regulatory subunit B56α associates with c-myc and negatively regulates c-myc accumulation

Arnold, H. K., & Sears, R. C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2832-2844.2006 · Cited by 251 · see citing works

CIP2A Is Associated with Human Breast Cancer Aggressivity

Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3283 · Cited by 221 · see citing works

Direct interaction between the inhibitor 2 and ceramide via sphingolipid‐protein binding is involved in the regulation of protein phosphatase 2A activity and signaling

Mukhopadhyay, A., Saddoughi, S. A., Song, P., Sultan, I. Y., Ponnusamy, S., Senkal, C. E., Snook, C. F., Arnold, H., Sears, R. C., Hanniui, Y. A., et al. (2008) · The FASEB Journal · doi:10.1096/fj.08-120550 · Cited by 208 · see citing works

Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models.

Azuma, H., Takahara, S., Ichimaru, N., Wang, J. D., Itoh, Y., Otsuki, Y., Morimoto, J., Fukui, R., Hoshiga, M., Ishihara, T., et al. (2002) · PubMed · Cited by 193 · see citing works

Role of serine/threonine protein phosphatase 2A in cancer

Schönthal, A. H. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00561-4 · Cited by 186 · see citing works

Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

Switzer, C. H., Cheng, R. Y. S., Vitek, T. M., Christensen, D. J., Wink, D. A., & Vitek, M. P. (2011) · Oncogene · doi:10.1038/onc.2010.622 · Cited by 171 · see citing works

Immortalization with telomerase of the Nestin-positive cells of the human pancreas.

Lee, K. M., Nguyen, C., Ulrich, A., Pour, P., & Ouellette, M. (2003) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/s0006-291x(03)00086-x · Cited by 160 · see citing works

Methylation of the Protein Phosphatase 2A Catalytic Subunit Is Essential for Association of Bα Regulatory Subunit But Not SG2NA, Striatin, or Polyomavirus Middle Tumor Antigen

Yu, X. X., Du, X., Moreno, C. S., Green, R. E., Ogris, E., Feng, Q., Chou, L., McQuoid, M. J., & Pallas, D. C. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.1.185 · Cited by 160 · see citing works

A specific PP2A regulatory subunit, B56γ, mediates DNA damage‐induced dephosphorylation of p53 at Thr55

Li, H., Cai, X., Shouse, G., Piluso, L. G., & Liu, X. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601519 · Cited by 159 · see citing works

c-MYC Activation in Primary and Metastatic Ductal Adenocarcinoma of the Pancreas: Incidence, Mechanisms, and Clinical Significance

Schleger, C., Verbeke, C. S., Hildenbrand, R., Zentgraf, H., & Bleyl, U. (2002) · Modern Pathology · doi:10.1038/modpathol.3880547 · Cited by 153 · see citing works

FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma

Liu, Q., Zhao, X. B., Frissora, F. W., Ma, Y., Santhanam, R., Jarjoura, D. G., Lehman, A., Perrotti, D., Chen, C., Dalton, J. T., et al. (2007) · Blood · doi:10.1182/blood-2006-10-053884 · Cited by 146 · see citing works

Mechanisms of MYC stabilization in human malignancies

Junttila, M. R., & Westermarck, J. K. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5492 · Cited by 144 · see citing works

Genomic DNA-Chip Hybridization Reveals a Higher Incidence of Genomic Amplifications in Pancreatic Cancer than Conventional Comparative Genomic Hybridization and Leads to the Identification of Novel Candidate Genes

Holzmann, K., Kohlhammer, H., Schwäenen, C., Weßendorf, S., Kestler, H. A., Schwoerer, A., Rau, B., Radlwimmer, B., Döhner, H., Lichter, P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0431 · Cited by 142 · see citing works

Pin1 Regulates the Dynamics of c-Myc DNA Binding To Facilitate Target Gene Regulation and Oncogenesis

Farrell, A. S., Pelz, C., Wang, X., Daniel, C. J., Wang, Z., Su, Y., Janghorban, M., Zhang, X., Morgan, C. W., Impey, S., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01455-12 · Cited by 140 · see citing works

SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target

Christensen, D. J., Chen, Y., Oddo, J., Matta, K. M., Neil, J. E., Davis, E. D., Volkheimer, A. D., Lanasa, M. C., Friedman, D. R., Goodman, B. K., et al. (2011) · Blood · doi:10.1182/blood-2011-04-351072 · Cited by 128 · see citing works

Apolipoprotein E and Peptide Mimetics Modulate Inflammation by Binding the SET Protein and Activating Protein Phosphatase 2A

Christensen, D. J., Ohkubo, N., Oddo, J., Van Kanegan, M. J., Neil, J., Li, F., Colton, C. A., & Vitek, M. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002847 · Cited by 125 · see citing works

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

Cristóbal, I., García-Ortí, L., Cirauqui, C., Cortés-Lavaud, X., Garcı́a-Sánchez, A., Calasanz, M. J., & Odero, M. D. (2011) · Haematologica · doi:10.3324/haematol.2011.050542 · Cited by 123 · see citing works

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

Agarwal, A., MacKenzie, R. J., Pippa, R., Eide, C. A., Oddo, J., Tyner, J. W., Sears, R. C., Vitek, M. P., Odero, M. D., Christensen, D. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2575 · Cited by 123 · see citing works

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

Oaks, J. J., Santhanam, R., Walker, C. J., Roof, S. R., Harb, J. G., Ferenchak, G. J., Eisfeld, A., Brocklyn, J. R. V., Briesewitz, R., Saddoughi, S. A., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492181 · Cited by 111 · see citing works

A tumor suppressor role for PP2A-B56α through negative regulation of c-Myc and other key oncoproteins

Arnold, H. K., & Sears, R. C. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9128-9 · Cited by 111 · see citing works

Induction of Apoptosis in Human Bladder Cancer Cells In Vitro and In Vivo Caused by FTY720 Treatment

Azuma, H., Takahara, S., Horie, S., Muto, S., Otsuki, Y., & Katsuoka, Y. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000064938.32318.91 · Cited by 109 · see citing works

PP2A Regulates BCL-2 Phosphorylation and Proteasome-mediated Degradation at the Endoplasmic Reticulum

Lin, S., Bassik, M. C., Suh, H., Nishino, M., Arroyo, J. D., Hahn, W. C., Korsmeyer, S. J., & Roberts, T. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602648200 · Cited by 102 · see citing works

FTY720: A Promising Agent for Treatment of Metastatic Hepatocellular Carcinoma

Lee, T. K., Man, K., Ho, J. W., Wang, X. H., Poon, R. T. P., Xu, Y. Y., Ng, K. T., Chu, A. C., Sun, C. K.-W., Ng, I. O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0447 · Cited by 98 · see citing works

SV40 small T antigen and PP2A phosphatase in cell transformation

Sablina, A. A., & Hahn, W. C. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9116-0 · Cited by 95 · see citing works

Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression

Zhang, X., Farrell, A. S., Daniel, C. J., Arnold, H., Scanlan, C., Laraway, B. J., Janghorban, M., Lum, L., Chen, D., Troxell, M. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100764108 · Cited by 81 · see citing works

FTY720, a fungus metabolite, inhibits in vivo growth of androgen‐independent prostate cancer

Chua, C. W., Lee, D. T., Ling, M., Zhou, C., Man, K., Ho, J., Chan, F. L., Wang, X., & Wong, Y. C. (2005) · International Journal of Cancer · doi:10.1002/ijc.21243 · Cited by 79 · see citing works

Protein Phosphatase 2A Negatively Regulates Eukaryotic Initiation Factor 4E Phosphorylation and eIF4F Assembly through Direct Dephosphorylation of Mnk and eIF4E

Li, Y., Yue, P., Deng, X., Ueda, T., Fukunaga, R., Khuri, F. R., & Sun, S. (2010) · Neoplasia · doi:10.1593/neo.10704 · Cited by 78 · see citing works

Ceramide in Apoptotic Signaling and Anticancer Therapy

Lin, C., Chen, C., & Lin, Y.-F. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706777441986 · Cited by 76 · see citing works

Reactivating PP2A by FTY720 as a Novel therapy for AML with C‐KIT tyrosine kinase domain mutation

Yang, Y., Huang, Q., Lu, Y., Li, X., & Huang, S. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24003 · Cited by 70 · see citing works

Aberrant signaling pathways in pancreatic cancer: A two compartment view

McCleary‐Wheeler, A. L., McWilliams, R. R., & Fernández-Zapico, M. E. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20827 · Cited by 65 · see citing works

SET complex in serous epithelial ovarian cancer

Ouellet, V., Page, C. L., Guyot, M., Lussier, C., Tonin, P. N., Provencher, D. M., & Mes‐Masson, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.22054 · Cited by 61 · see citing works

Modulation of Protein Phosphatase 2A Activity Alters Androgen-Independent Growth of Prostate Cancer Cells: Therapeutic Implications

Bhardwaj, A., Singh, S., Srivastava, S. K., Honkanen, R. E., Reed, E., & Singh, A. P. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1096 · Cited by 60 · see citing works

DNA Copy Number Changes and Evaluation of MYC, IGF1R, and FES Amplification in Xenografts of Pancreatic Adenocarcinoma

Armengol, G., Knuutila, S., Lluı́s, F., Capellá, G., Miró, R., & Caballín, M. R. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00118-1 · Cited by 58 · see citing works

Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK

Nica, A. F., Tsao, C. C., Watt, J. C., Jiffar, T., Kurinna, S. M., Jurasz, P., Konopleva, M. Y., Andreeff, M., Radomski, M. W., & Ruvolo, P. P. (2008) · Cell Cycle · doi:10.4161/cc.7.21.6894 · Cited by 58 · see citing works

Ceramide Produces Apoptosis Through Induction of p27kip1by Protein Phosphatase 2A-dependent Akt Dephosphorylation in PC-3 Prostate Cancer Cells

Kim, S. W., Kim, H. J., Chun, Y. J., & Kim, M. Y. (2010) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2010.511553 · Cited by 43 · see citing works

CIP2A expression is associated with altered expression of epithelial–mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma

Wang, L., Gu, F., Ma, N., Zhang, L., Bian, J., & Cao, H. (2013) · Tumor Biology · doi:10.1007/s13277-013-0775-2 · Cited by 34 · see citing works

Prolonged and symptomatic bradycardia following a single dose of fingolimod

Faber, H., Fischer, H.-J., & Weber, F. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512447596 · Cited by 32 · see citing works

Gene-expression profiling in pancreatic cancer

Lopez-Casas, P. P., & López-Fernández, L. A. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.43 · Cited by 32 · see citing works

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875 · see citing works

Strategies to Inhibit Myc and Their Clinical Applicability

Whitfield, J. R., Beaulieu, M.-È., & Soucek, L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00010 · Cited by 295 · see citing works

Glutamine Metabolism in Cancer

Li, T., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_2 · Cited by 240 · see citing works

Therapeutic targeting of PP2A

O’Connor, C. M., Perl, A. L., Léonard, D., Sangodkar, J., & Narla, G. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.008 · Cited by 181 · see citing works

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism

Vaseva, A. V., Blake, D. R., Gilbert, T. S. K., Ng, S., Hostetter, G. H., Azam, S. H., Ozkan‐Dagliyan, I., Gautam, P., Bryant, K. L., Pearce, K. H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.001 · Cited by 181 · see citing works

Mission Possible: Advances in MYC Therapeutic Targeting in Cancer

Allen-Petersen, B. L., & Sears, R. C. (2019) · BioDrugs · doi:10.1007/s40259-019-00370-5 · Cited by 143 · see citing works

MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance

Farrell, A. S., Joly, M. M., Allen-Petersen, B. L., Worth, P. J., Lanciault, C., Sauer, D., Link, J. M., Pelz, C., Heiser, L. M., Morton, J. P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01967-6 · Cited by 131 · see citing works

Glutamine Metabolism in Cancer

Li, T., Copeland, C., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_2 · Cited by 130 · see citing works

Targeting PP2A in cancer: Combination therapies

Mazhar, S., Taylor, S. E., Sangodkar, J., & Narla, G. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.08.020 · Cited by 127 · see citing works

Target c-Myc to treat pancreatic cancer

Ala, M. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.2017223 · Cited by 119 · see citing works

Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer

Kauko, O., & Westermarck, J. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.01.005 · Cited by 111 · see citing works

The long journey to bring a Myc inhibitor to the clinic

Whitfield, J. R., & Soucek, L. (2021) · The Journal of Cell Biology · doi:10.1083/jcb.202103090 · Cited by 97 · see citing works

Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56

Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., Sarek, G., Ojala, P. M., Rao, Z., Xu, W., et al. (2017) · The EMBO Reports · doi:10.15252/embr.201642788 · Cited by 95 · see citing works

Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer

Liu, H., Gu, Y., Wang, H., Yin, J., Zheng, G., Zhang, Z., Lu, M., Wang, C., & He, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.3818 · Cited by 94 · see citing works

Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy

Pan, X., Pei, J., Wang, A., Wen, S., Feng, L., Bu, F., Zhu, Y., Zhang, L., Wang, G., & Ouyang, L. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.022 · Cited by 91 · see citing works

Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine

Lankadasari, M. B., Aparna, J. S., Mohammed, S., James, S., Aoki, K., Binu, V. S. N., Nair, S., & Harikumar, K. B. (2018) · Theranostics · doi:10.7150/thno.25308 · Cited by 87 · see citing works

Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma

Allen-Petersen, B. L., Risom, T., Feng, Z., Wang, Z., Jenny, Z. P., Thoma, M. C., Pelz, K. R., Morton, J. P., Sansom, O. J., Lopez, C. D., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0717 · Cited by 85 · see citing works

Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer

Chien, W., Sun, Q.-Y., Lee, K. L., Ding, L.-W., Wuensche, P., Torres-Fernandez, L. A., Tan, S. Z., Tokatly, I., Zaiden, N., Poellinger, L., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.01.002 · Cited by 80 · see citing works

Concepts to Target MYC in Pancreatic Cancer

Wirth, M., Mahboobi, S., Krämer, O. H., & Schneider, G. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0050 · Cited by 79 · see citing works

The role of CIP2A in cancer: A review and update

Soofiyani, S. R., Hejazi, M. S., & Baradaran, B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.146 · Cited by 72 · see citing works

Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): An oncoprotein with many hands

De, P. K., Carlson, J. H., Leyland-Jones, B. R., & Dey, N. (2014) · Oncotarget · doi:10.18632/oncotarget.2127 · Cited by 72 · see citing works

Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer

Blake, D. R., Vaseva, A. V., Hodge, R. G., Kline, M. P., Gilbert, T. S. K., Tyagi, V., Huang, D., Whiten, G. C., Larson, J. E., Wang, X., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aav7259 · Cited by 70 · see citing works

The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells

Parasido, E., Avetian, G. S., Naeem, A., Graham, G. T., Pishvaian, M. J., Glasgow, E. F., Mudambi, S., Lee, Y., Ihemelandu, C. U., Choudhry, M. U., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0191 · Cited by 67 · see citing works

Redox inhibition of protein phosphatase PP2A: Potential implications in oncogenesis and its progression

Raman, D., & Pervaiz, S. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101105 · Cited by 55 · see citing works

Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression

Liu, C., Huang, T., Chen, Y., Chen, J.-L., Chu, P., Huang, C.-T., Wang, W.-L., Lau, K.-Y., Dai, M., Shiau, C., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.032 · Cited by 51 · see citing works

Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis

Enjoji, S., Yabe, R., Tsuji, S., Yoshimura, K., Kawasaki, H., Sakurai, M., Sakai, Y., Takenouchi, H., Yoshino, S., Hazama, S., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0393 · Cited by 49 · see citing works

Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity

Risom, T., Wang, X., Liang, J. B., Zhang, X., Pelz, C., Campbell, L. G., Eng, J., Chin, K., Farrington, C. C., Narla, G., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126390 · Cited by 48 · see citing works

Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers

Farrington, C. C., Yuan, E., Mazhar, S., Izadmehr, S., Hurst, L., Allen-Petersen, B. L., Janghorban, M., Chung, E. M., Wolczanski, G., Galsky, M. D., et al. (2020) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)49933-9 · Cited by 47 · see citing works

miR-21-5p promotes lung adenocarcinoma progression partially through targeting SET/TAF-Iα

Zhong, J., Ren, X., Chen, Z., Zhang, H., Zhou, L., Yuan, J., Li, P., Chen, X., Liu, W., Wu, D., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.06.014 · Cited by 41 · see citing works

Glucose Metabolism Reprogrammed by Overexpression of IKKϵ Promotes Pancreatic Tumor Growth

Zubair, H., Azim, S., Srivastava, S. K., Ahmad, A., Bhardwaj, A., Khan, M. A., Patel, G. K., Arora, S., Carter, J. E., Singh, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1666 · Cited by 40 · see citing works

Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates

De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40 · see citing works

Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells

Kim, M.-O., Choe, M. H., Yoon, Y. N., Ahn, J., Yoo, M., Jung, K., An, S., Hwang, S., Oh, J. S., & Kim, J. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.009 · Cited by 38 · see citing works

Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers

Farrington, C. C., Yuan, E., Mazhar, S., Izadmehr, S., Hurst, L., Allen-Petersen, B. L., Janghorban, M., Chung, E. M., Wolczanski, G., Galsky, M. D., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011443 · Cited by 38 · see citing works

A comprehensive and perspective view of oncoprotein SET in cancer

Bayarkhangai, B., Noureldin, S., Yu, L., Zhao, N., Gu, Y., Xu, H., & Guo, C. (2018) · Cancer Medicine · doi:10.1002/cam4.1526 · Cited by 38 · see citing works

Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis

Hu, X., Garcia, C., Fazli, L., Gleave, M. E., Vitek, M. P., Jansen, M., Christensen, D. J., & Mulholland, D. J. (2015) · Scientific Reports · doi:10.1038/srep15182 · Cited by 37 · see citing works

SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell

Liu, H., Gu, Y., Yin, J., Zheng, G., Wang, C., Zhang, Z., Deng, M., Liu, J., Jia, X., & He, Z. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.08.010 · Cited by 36 · see citing works

The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias

Pippa, R., & Odero, M. D. (2020) · Cells · doi:10.3390/cells9030544 · Cited by 36 · see citing works

The interaction of SET and protein phosphatase 2A as target for cancer therapy

Dacol, E. C., Wang, S., Chen, Y., & Lepique, A. P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188578 · Cited by 34 · see citing works

Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer

Cristóbal, I., Gónzález-Alonso, P., Daoud, L., Solano, E. C., Torrejón, B., Manso, R., Madoz‐Gúrpide, J., Rojo, F., & García‐Foncillas, J. (2015) · Marine Drugs · doi:10.3390/md13063276 · Cited by 32 · see citing works

MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia

Pippa, R., Dominguez, A., Malumbres, R., Endo, A., Arriazu, E., Marcotegui, N., Guruceaga, E., & Odero, M. D. (2016) · Oncotarget · doi:10.18632/oncotarget.9840 · Cited by 32 · see citing works

Isoliensinine induces dephosphorylation of NF-κB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction

Shu, G., Zhang, L., Jiang, S., Cheng, Z., Wang, G., Huang, X., & Yang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.9603 · Cited by 31 · see citing works

Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review

Cristóbal, I., Madoz‐Gúrpide, J., Manso, R., Gónzález-Alonso, P., Rojo, F., & García‐Foncillas, J. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1162774 · Cited by 29 · see citing works

Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer

Hung, M., & Chen, K. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1336226 · Cited by 28 · see citing works

SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation

Almeida, L. O., Neto, M. P. C., Sousa, L. O., Tannous, M. A., Curti, C., & Leopoldino, A. M. (2017) · Oncotarget · doi:10.18632/oncotarget.15818 · Cited by 28 · see citing works

The Molecular ‘Myc-anisms’ behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics

McAnulty, J., & DiFeo, A. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249486 · Cited by 27 · see citing works

SET contributes to the epithelial-mesenchymal transition of pancreatic cancer

Mody, H. R., Hung, S. W., Naidu, K., Lee, H., Gilbert, C. A., Hoang, T. T., Pathak, R. K., Manoharan, R., Muruganandan, S., & Govindarajan, R. (2017) · Oncotarget · doi:10.18632/oncotarget.19067 · Cited by 27 · see citing works

PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen

Tinsley, S. L., & Allen-Petersen, B. L. (2022) · NAR Cancer · doi:10.1093/narcan/zcac002 · Cited by 25 · see citing works

Peroxynitrite promotes serine-62 phosphorylation-dependent stabilization of the oncoprotein c-Myc

Raman, D., Chong, S. J. F., Iskandar, K. B., Hirpara, J. L., & Pervaiz, S. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101587 · Cited by 25 · see citing works

Understanding the regulatory landscape of protein phosphatase 2A (PP2A): Pharmacological modulators and potential therapeutics

Neale, D. B., Morris, J. C., Verrills, N. M., & Ammit, A. J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108834 · Cited by 24 · see citing works

Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer

Cristóbal, I., Torrejón, B., Rubio, J., Santos, A., Pedregal, M., Caramés, C., Zazo, S., Luque, M., Sanz-Álvarez, M., Madoz‐Gúrpide, J., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030346 · Cited by 23 · see citing works

The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma

Enjoji, S., Yabe, R., Fujiwara, N., Tsuji, S., Vitek, M. P., Mizuno, T., Nakagawa, T., Usui, T., Ohama, T., & Sato, K. (2015) · Journal of Veterinary Medical Science · doi:10.1292/jvms.15-0193 · Cited by 23 · see citing works

Pathologic significance of SET/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS)

Jiang, S., Xu, S., Chen, H., Liu, X., Tang, Z., Cui, Y., & Liu, J. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.11.010 · Cited by 23 · see citing works

Vascular smooth muscle RhoA counteracts abdominal aortic aneurysm formation by modulating MAP4K4 activity

Molla, M. R., Shimizu, A., Komeno, M., Rahman, N. I. A., Soh, J. E. C., Nguyen, L. K. C., Khan, M. R., Tesega, W. W., Chen, S., Pang, X., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04042-z · Cited by 22 · see citing works

The role of phosphoprotein phosphatases catalytic subunit genes in pancreatic cancer

Hang, J., Lau, S. Y. F., Yin, R., Zhu, L., Zhou, S., Yuan, X., & Wu, L. (2020) · Bioscience Reports · doi:10.1042/bsr20203282 · Cited by 21 · see citing works

Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family member Survivin

Chang, W.-H., Liu, Y., Hammes, E. A., Bryant, K. L., Cerione, R. A., & Antonyak, M. A. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102842 · Cited by 21 · see citing works

Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity

Sacco, A., Federico, C., Todoerti, K., Ziccheddu, B., Palermo, V., Giacomini, A., Ravelli, C., Maccarinelli, F., Bianchi, G., Belotti, A., et al. (2021) · Blood · doi:10.1182/blood.2020010572 · Cited by 20 · see citing works

Serine/threonine phosphatases in osteoclastogenesis and bone resorption

Karkache, I. Y., Damodaran, J. R., Molstad, D. H. H., & Bradley, E. W. (2020) · Gene · doi:10.1016/j.gene.2020.145362 · Cited by 20 · see citing works

Stable SET knockdown in breast cell carcinoma inhibits cell migration and invasion

Li, J., Yang, X., Ren, X., Meng, X.-J., Huang, H., Zhao, Q.-H., Yuan, J., Hong, W., Xia, B., Huang, X., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.013 · Cited by 19 · see citing works

Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications

Tian, L., Zhang, X., Haesen, D., Bravo, J., Fominaya, J. M., Choquet, S., Zini, J. M., Loisel, S., Waelkens, E., Janssens, V., et al. (2017) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-017-9633-1 · Cited by 19 · see citing works

Phosphatases and solid tumors: focus on glioblastoma initiation, progression and recurrences

Dedobbeleer, M., Willems, E., Freeman, S. D., Lombard, A., Goffart, N., & Rogister, B. (2017) · Biochemical Journal · doi:10.1042/bcj20170112 · Cited by 19 · see citing works

Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth

Williams, A. P., Garner, E. F., Waters, A. M., Stafman, L. L., Aye, J. M., Markert, H. R., Stewart, J. E., & Beierle, E. A. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.09.011 · Cited by 18 · see citing works

2,5-Dimethyl Celecoxib Inhibits Proliferation and Cell Cycle and Induces Apoptosis in Glioblastoma by Suppressing CIP2A/PP2A/Akt Signaling Axis

Gao, D., Nyalali, A. M. K., Hou, Y., Xu, Y., Zhou, J., Zhao, W., Huang, B., & Li, F. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01773-8 · Cited by 16 · see citing works

Cancer progression by the okadaic acid class of tumor promoters and endogenous protein inhibitors of PP2A, SET and CIP2A

Fujiki, H., Sueoka, E., Watanabe, T., Komori, A., & Suganuma, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04800-4 · Cited by 15 · see citing works

Rationale for MYC imaging and targeting in pancreatic cancer

Schneider, G., Wirth, M., Keller, U. B., & Saur, D. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00843-1 · Cited by 15 · see citing works

Thirty years of SET/TAF1β/I2PP2A: from the identification of the biological functions to its implications in cancer and Alzheimer’s disease

Mambro, A. D., & Esposito, M. T. (2022) · Bioscience Reports · doi:10.1042/bsr20221280 · Cited by 12 · see citing works

The next decade of SET: from an oncoprotein to beyond

Yao, H., Zhang, M., & Wang, D. (2023) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjad082 · Cited by 11 · see citing works

The Pivotal Role of Protein Phosphatase 2A (PP2A) in Brain Tumors

Cucinotta, L., Filippone, A., Casili, G., Lanza, M., Bova, V., Capra, A. P., Giuffrida, R., Colarossi, C., Sciacca, D., Paterniti, I., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415717 · Cited by 11 · see citing works

PP2A inhibitor SET promotes mTORC1 and Bmi1 signaling through Akt activation and maintains the colony-formation ability of cancer cells

Kohyanagi, N., Kitamura, N., Ikeda, S., Shibutani, S., Sato, K., & Ohama, T. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105584 · Cited by 11 · see citing works

GnRH regulates the expression of its receptor accessory protein SET in pituitary gonadotropes

Avet, C., Denoyelle, C., L’Hôte, D., Petit, F., Guigon, C. J., Cohen-Tannoudji, J., & Simon, V. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201494 · Cited by 11 · see citing works

Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma

Goto, R. N., Sobral, L. M., Padovani, K. S., Garcia, C. B., da Silva, G. F., Vitek, M. P., & Leopoldino, A. M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173268 · Cited by 11 · see citing works

AKR1B10 dictates c-Myc stability to suppress colorectal cancer metastasis via PP2A nitration

Wu, X., Huang, S., Gao, J., Huang, S., Chen, L., Zhao, Z., Pu, R., Ma, X., Liu, X., He, W., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv6937 · Cited by 10 · see citing works

CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma

Chao, T., Maa, H., Wang, C., Pei, D., Liang, Y., Yang, Y., Chou, S., & Chen, Y. (2016) · Apmis · doi:10.1111/apm.12602 · Cited by 10 · see citing works

SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition

Aguilar‐Valdés, A., Noriega, L. G., Tovar, A. R., Ibarra-Sánchez, M. D. J., Sosa‐Hernández, V. A., Maravillas‐Montero, J. L., & Martínez‐Aguilar, J. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.03.018 · Cited by 10 · see citing works

PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449

Galiger, C., Dahlhaus, M., Vitek, M. P., Debatin, K., & Beltinger, C. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.744984 · Cited by 10 · see citing works

MYC and non-small cell lung cancer: A comprehensive review

Kenzerki, M. E., Ahmadi, M., Mousavi, P., & Ghafouri‐Fard, S. (2023) · Human Gene · doi:10.1016/j.humgen.2023.201185 · Cited by 10 · see citing works

KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development

Tinsley, S. L., Chianis, E. R. D., Shelley, R. A., Mall, G. K., Dhiman, A., Baral, G., Kothandaraman, H., Thoma, M. C., English, I. A., Daniel, C. J., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03196-w · Cited by 9 · see citing works

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML

Mambro, A. D., Arroyo-Berdugo, Y., Fioretti, T., Randles, M. J., Cozzuto, L., Rajeeve, V., Cevenini, A., Austin, M. J., Esposito, G., Ponomarenko, J. V., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02840-1 · Cited by 9 · see citing works

The first-in-class pro-apoptotic peptide PEP-010 is effective in monotherapy and in combination with paclitaxel on resistant ovarian adenocarcinoma cell models

Lacroix, A., Farhat, R., Robert, A., Brenner, C., Wiels, J., & Germini, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1444973 · Cited by 9 · see citing works

HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity

Dobersch, S., Yamamoto, N., Schutter, A., Cavender, S. M., Robertson, T. M., Kartha, N., Samraj, A. N., Doron, B., Poole, L. A., Wladyka, C. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60129-1 · Cited by 8 · see citing works

The Interaction Mechanism of Intrinsically Disordered PP2A Inhibitor Proteins ARPP-16 and ARPP-19 With PP2A

Thapa, C. J., Roivas, P., Haataja, T., Permi, P., & Pentikäinen, U. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.650881 · Cited by 8 · see citing works

Small-molecule modulators of B56-PP2A restore 4E-BP function to suppress eIF4E-dependent translation in cancer cells

Lum, M. A., Jonas, K. A., Parmar, S., Black, A. R., O’Connor, C. M., Dobersch, S., Yamamoto, N., Robertson, T. M., Schutter, A., Giambi, M., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci176093 · Cited by 7 · see citing works

Characterization of SET/I2PP2A Isoforms in Dogs

Yabe, R., Fujiwara, N., Mizuno, T., Usui, T., Ohama, T., & Sato, K. (2014) · Journal of Veterinary Medical Science · doi:10.1292/jvms.14-0209 · Cited by 7 · see citing works

MiR-145-5p regulates granulosa cell proliferation by targeting the SET gene in KGN cells

LINGLING, G., QINGXING, Y., Xu, J., Wang, W., & Lu, D. A. N. (2024) · Journal of Reproduction and Development · doi:10.1262/jrd.2024-053 · Cited by 6 · see citing works

Phosphopeptide Enrichment and LC-MS/MS Analysis to Study the Phosphoproteome of Recombinant Chinese Hamster Ovary Cells

Henry, M. A., Coleman, O., Prashant, P., CLYNES, M. M., & Meleady, P. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6972-2_13 · Cited by 6 · see citing works

Data mining analysis of the PP2A cell cycle axis in mesothelioma patients

Pippa, R., Boffo, S., Odero, M. D., & Giordano, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29414 · Cited by 6 · see citing works

Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer

Tozuka, K., Wongsirisin, P., Nagai, S. E., Kobayashi, Y., Kanno, M., Kubo, K., Takai, K., Inoue, K., Matsumoto, H., Shimizu, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93620-y · Cited by 6 · see citing works

Template activating factor-I epigenetically regulates the TERT transcription in human cancer cells

Kato, K., Kawaguchi, A., & Nagata, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-97009-9 · Cited by 5 · see citing works

Upregulated SET Promotes Cell Survival Through Activating Akt/NF-κB Signal in Colorectal Carcinoma

Zhu, J., Shi, L., Du, G., Li, L., & Liu, M. (2020) · Cancer Management and Research · doi:10.2147/cmar.s255930 · Cited by 4 · see citing works

Phosphorylation of protein phosphatase 2A facilitated an early stage of chemical carcinogenesis

Ishii, Y., Kuroda, K., Matsushita, K., Yokoo, Y., Takasu, S., Kijima, A., Nohmi, T., Ogawa, K., & Umemura, T. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.10.009 · Cited by 3 · see citing works

Co-expression of FOXL1 and PP2A inhibits proliferation inducing apoptosis in pancreatic cancer cells via promoting TRAIL and reducing phosphorylated MYC

LI, Y., Yu, D., Sheng, W., SONG, H., Li, Y., & Dong, M. (2016) · Oncology Reports · doi:10.3892/or.2016.4592 · Cited by 3 · see citing works

Protein phosphatase 2A as a therapeutic target in pancreatic cancer: past insights, recent advances, and future directions

Shah, V. M., & Sears, R. C. (2025) · Current Opinion in Physiology · doi:10.1016/j.cophys.2025.100849 · Cited by 2 · see citing works

Distribution of SET/I2PP2A protein in gastrointestinal tissues

Umata, K., Sakai, Y., Ikeda, S., Tsuji, S., Kawasaki, H., Ohama, T., & Sato, K. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222845 · Cited by 2 · see citing works

A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC

Luo, Y., Biswas, H., Makinwa, Y., Liu, S., Dong, Z., Liu, J., Zhang, J., & Zou, Y. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217790 · Cited by 1 · see citing works

Decreased PP2A expression and activity represent a therapeutic target for plexiform neurofibroma

Yue, M., Wang, Y., Gu, J., Zhang, C., Chen, Y., Gao, A., Choi, K., Wu, Z., Wang, Z., Pundavela, J., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02315-w · Cited by 1 · see citing works

Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC

Pfeffer, C. M., Clifford, S. J., Karim, S. A., Chianis, E. R. D., N, H. B., Gartenhaus, L. E., Kay, E. F., Baral, G., Hoffman, E. G., Utturkar, S. M., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0970 · Cited by 1 · see citing works

Targeting PP2A inhibitors as a novel anti-cancer strategy

Ohama, T. (2015) · Folia Pharmacologica Japonica · doi:10.1254/fpj.145.293 · Cited by 1 · see citing works

Potenciais mecanismos de regulação da fosfatase PTEN pelas proteínas SET e PP2A e seu envolvimento na predisposição ao carcinoma bucal

Matsumoto, C. S. (2016) · doi:10.11606/t.60.2016.tde-06072016-105354

Estudo in vitro e in vivo de novos compostos: com alvo-específico (hnRNP K e SET) ou com ação na mitocôndria para uso como antitumoral em carcinoma oral ou como citoprotetor em célula não-tumoral

Goto, R. N. (2017) · doi:10.11606/t.60.2017.tde-23112017-161303

Oncogenes and Tumor Suppressors Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer

Farrell, A. S., Allen-petersen, B., Daniel, C. J., Wang, X., Wang, Z., Rodriguez, S., Impey, S., Vitek, M. P., Lopez, C., Christensen, D. J., et al. (2016)

Abstract 1976: Targeting the PP2A tumor suppressor for the treatment of human pancreatic cancer.

Farrell, A., Daniel, C. J., Wang, Z., Allen-Petersen, B. L., Christensen, D. J., Sheppard, B. C., Lopez, C. D., & Sears, R. C. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-1976 · Cited by 1 · see citing works

Abstract B21: Protein phosphatase 2A (PP2A) activation functions synergistically with kinase inhibition in pancreatic cancer

Allen-Petersen, B. L., Farrell, A. S., Jenny, Z. P., Daniel, C. J., Wang, Z., Lopez, C. D., Christensen, D. J., Narla, G., Sheppard, B. C., & Sears, R. C. (2015) · Molecular Cancer Research · doi:10.1158/1557-3125.myc15-b21

Abstract A104: Phosphatase activation and kinase inhibition as a novel therapeutic strategy for pancreatic cancer

Allen-Petersen, B. L., Farrell, A. S., Daniel, C. J., Wang, Z., Lopez, C. D., Christensen, D. J., Sheppard, B. C., & Sears, R. C. (2015) · Cancer Research · doi:10.1158/1538-7445.panca2014-a104

The interaction of SET and protein phosphatase 2A as target for cancer therapy

Dacol, E. C., Wang, S., Chen, Y., & Lepique, A. P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188578 · Cited by 34 · see citing works